Nectar Lifesciences Ltd. (NECLIFE) AI Stock Analysis

• Market Cap: ₹3.18B
• Dividend Yield: N/A
• Average Volume (3M): 34.32K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.83
• Revenue Growth: -30.27%
• EPS Growth: -3470.06%
• Country: IN
• Employees: 1,686
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -7.85
• Shares Outstanding: 224,260,970
• 10 Day Avg. Volume: 25,321
• 30 Day Avg. Volume: 34,323
• PEG Ratio: <0.01
• Price to Book (P/B): 0.56
• Price to Sales (P/S): 0.32
• P/FCF Ratio: 4.30
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 50 Neutral
• Price Target: ₹14.50 ▲(2.40% Upside)

The overall stock score is primarily influenced by financial performance challenges, including inconsistent profitability and cash flow volatility. Technical analysis suggests a neutral trend with no strong momentum, while valuation concerns are significant due to a negative P/E ratio. The absence of earnings call data and notable corporate events means these factors do not impact the score.

Positive Factors

Market Diversification

Nectar Lifesciences Ltd.'s diverse product offerings in pharmaceuticals, nutraceuticals, and food products provide resilience against sector-specific downturns, enhancing long-term stability and growth potential.

Strategic Partnerships

Strategic partnerships with distributors and retailers enhance Nectar Lifesciences Ltd.'s market reach and distribution capabilities, supporting sustained revenue growth and competitive positioning.

Export Focus

Nectar Lifesciences Ltd.'s focus on exporting to markets that value natural health products leverages global demand trends, providing a durable revenue stream and growth opportunities.

Negative Factors

Profitability Challenges

Negative net profit margins and declining revenue growth indicate challenges in maintaining profitability, which could hinder long-term financial health and shareholder value.

Cash Flow Volatility

Volatile cash flow metrics suggest inconsistent cash generation, potentially impacting Nectar Lifesciences Ltd.'s ability to fund operations and invest in growth initiatives sustainably.

Return on Equity

Negative return on equity reflects challenges in generating returns for shareholders, which may affect investor confidence and the company's ability to attract capital.

Nectar Lifesciences Ltd. Business Overview & Revenue Model

Company Description

Nectar Lifesciences Ltd. (NECLIFE) is a leading player in the life sciences sector, primarily focusing on the production and export of high-quality honey, bee products, and other natural health products. The company is engaged in various segments including pharmaceuticals, nutraceuticals, and food products, catering to both domestic and international markets with a commitment to quality and sustainability. NECLIFE also emphasizes research and development, promoting innovative solutions in the health and wellness space.

How the Company Makes Money

Nectar Lifesciences Ltd. generates revenue through multiple key streams, primarily from the sale of honey and its by-products, which are distributed to both retail and wholesale markets. The company also profits from its pharmaceutical and nutraceutical products, which are marketed to health-conscious consumers and healthcare providers. Additionally, NECLIFE has established strategic partnerships with various distributors and retailers, enhancing its market reach and contributing to its overall earnings. The company’s focus on exports, particularly to markets that value natural health products, further amplifies its revenue potential.

Nectar Lifesciences Ltd. Financial Statement Overview

Summary

Nectar Lifesciences Ltd. faces challenges in maintaining consistent profitability and growth, as reflected in its income statement. The balance sheet indicates a stable capital structure but struggles with generating shareholder returns. Cash flow metrics show volatility, with some positive trends in recent periods. The company needs to address profitability and cash flow consistency to improve its financial health.

Income Statement

Nectar Lifesciences Ltd. has experienced significant volatility in its income statement metrics. The company reported a negative net profit margin and declining revenue growth rate in the latest period, indicating challenges in maintaining profitability and growth. The gross profit margin has also decreased over time, reflecting potential issues in cost management or pricing power. However, there were periods of positive EBIT and EBITDA margins, suggesting some operational efficiency during certain years.

Balance Sheet

The balance sheet shows a moderate debt-to-equity ratio, indicating a balanced approach to leveraging. However, the return on equity has been negative in recent periods, reflecting challenges in generating returns for shareholders. The equity ratio remains stable, suggesting a solid capital structure despite profitability issues.

Cash Flow

Cash flow analysis reveals fluctuating free cash flow growth, with a notable improvement in the latest period. The operating cash flow to net income ratio indicates some level of cash generation efficiency, although the free cash flow to net income ratio has been inconsistent. Overall, the cash flow position shows potential for improvement but remains volatile.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	15.92B	16.70B	16.84B	15.24B	16.69B	15.43B
Gross Profit	1.98B	3.02B	4.82B	579.91M	2.99B	2.58B
EBITDA	-1.26B	-245.66M	1.69B	994.97M	1.61B	612.51M
Net Income	-1.80B	-1.14B	49.95M	-241.83M	250.47M	-732.64M
Balance Sheet
Total Assets	0.00	20.47B	21.91B	21.89B	23.91B	23.88B
Cash, Cash Equivalents and Short-Term Investments	197.51M	272.63M	203.01M	178.94M	182.35M	259.58M
Total Debt	0.00	5.82B	6.36B	7.54B	8.60B	9.03B
Total Liabilities	-9.56B	10.91B	11.22B	11.25B	13.03B	13.26B
Stockholders Equity	9.56B	9.56B	10.69B	10.65B	10.88B	10.62B
Cash Flow
Free Cash Flow	0.00	1.26B	1.95B	1.04B	700.35M	-98.62M
Operating Cash Flow	0.00	1.69B	2.25B	1.34B	950.05M	213.79M
Investing Cash Flow	0.00	-419.30M	-170.25M	517.04M	166.44M	-286.24M
Financing Cash Flow	0.00	-1.28B	-2.05B	-1.86B	-1.19B	114.90M

Nectar Lifesciences Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 14.16
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:NECLIFE, the sentiment is Negative. The current price of 14.16 is below the 20-day moving average (MA) of 14.66, below the 50-day MA of 14.64, and below the 200-day MA of 20.19, indicating a bearish trend. The MACD of -0.01 indicates Negative momentum. The RSI at 47.08 is Neutral, neither overbought nor oversold. The STOCH value of 46.94 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:NECLIFE.

Nectar Lifesciences Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VENUSREM	72 Outperform	₹5.93B	11.03	―	―	13.32%	218.38%
INDSWFTLAB	70 Outperform	₹7.48B	2.97	―	―	-37.70%	-19.79%
SAKAR	66 Neutral	₹8.03B	40.62	―	―	24.20%	55.01%
MEDICAMEQ	65 Neutral	₹5.59B	50.25	―	0.24%	-9.16%	49.09%
ZIMLAB	63 Neutral	₹3.47B	52.70	―	―	-5.82%	-59.22%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NECLIFE	50 Neutral	₹3.18B	-1.77	―	―	-30.27%	-3470.06%

Nectar Lifesciences Ltd. Corporate Events

Nectar Lifesciences Announces Resignation of VP of Exports

Nectar Lifesciences Ltd. announced the resignation of Mr. Ashok Kumar from his position as Vice President (Exports), effective November 9, 2025. This change in senior management may impact the company’s export operations and strategic direction, potentially affecting its market positioning and stakeholder interests.

Nectar Lifesciences Ltd. Conducts 30th AGM with Emphasis on Stakeholder Engagement

Nectar Lifesciences Ltd. held its 30th Annual General Meeting (AGM) on September 29, 2025, via video conferencing, adhering to the relevant regulatory guidelines. The meeting, chaired by Managing Director Sanjiv Goyal, included participation from key directors and auditors. The AGM facilitated shareholder engagement and electronic voting, underscoring the company’s commitment to transparency and stakeholder involvement.

Nectar Lifesciences Ltd. Announces Virtual AGM for 2025

Nectar Lifesciences Ltd. has announced that its 30th Annual General Meeting (AGM) will be held on September 29, 2025, via video conferencing and other audio-visual means. This decision aligns with the guidelines issued by the Ministry of Corporate Affairs, ensuring compliance and accessibility for shareholders. The notice has been published in regional newspapers to inform stakeholders, reflecting the company’s commitment to transparency and regulatory adherence.

Nectar Lifesciences Ltd. Publishes Q2 2025 Financial Results

Nectar Lifesciences Ltd. has published its financial results for the quarter ending June 30, 2025, in major newspapers including Business Standard and Desh Sewak. This publication is part of the company’s compliance with regulatory requirements, ensuring transparency and keeping stakeholders informed about its financial performance.